Eli Lilly & Co.’s Mounjaro gained Chinese regulatory approval for weight less than a month after a similar therapy from Novo Nordisk A/S, fueling competition in a nation that’s among the ...

SHANGHAI (Reuters) -Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The drug, available in the form of a weekly jab, was first approved in the U.S. for diabetes under the brand name Mounjaro and later for weight loss under the name Zepbound. While China has only ...

Eli Lilly weight loss drug approved in China. Jul. 19, 2024 7:21 AM ET Eli Lilly and Company (LLY) Stock NVO, NONOF By: Dulan Lokuwithana, SA News Editor 6 Comments. Play (1min) ...

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Lilly's drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.

The Eli Lilly and Co. corporate headquarters are seen in Indianapolis on April 26, 2017. Eli Lilly has cut the prices of its two lowest doses of weight-loss drug Zepbound by releasing them as ...

Eli Lilly’s anti-diabetic medication Zepbound cuts the risk of developing Type 2 diabetes by 94 percent in pre-diabetic adults and or those who are overweight or obese, the company said Tuesday.